NCT03915405 - KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 26, 2019

Primary Completion Date

November 15, 2022

Study Completion Date

November 15, 2022

Conditions

Urothelial Carcinoma

Interventions

DRUG

KHK2455

orally, once daily.

DRUG

Avelumab

IV Administration

Trial Locations (9)

Kyowa Research Site ESP004, Madrid

Kyowa Research Site ESP001, Madrid

Kyowa Research Site USA001, St. Petersburg

Kyowa Research Site USA005, Iowa City

Kyowa Research Site USA007, Milwaukee

Kyowa Research Site USA 009, Houston

Kyowa Research Site USA006, Santa Fe

Kyowa Research Site ESP002, Barcelona

Kyowa Research Site ESP003, Barcelona